Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity ...
– Oral presentation at RAS Summit supports development of next-generation FTI in combination with KRASG12C inhibitors –
United States Alexandra Weingarten Francis Burrows Corporate Communications Exchange Commission Company Form
Source: eagletribune.com